NEURIZON THERAPEUTICS LIMITED (NUZ)
Share Price Analysis and Chart

03/07/2025

1

Speculative Buy

$0.42

147.06%

Neurizon Therapeutics signed an agreement with Elanco Animal Health for the rights to use Monapantel, the active ingredient in its drug NUZ-001. The deal also includes the use of non-clinical studies and manufacturing data for neurogenerative diseases.

Morgans reckons the undisclosed upfront payment is immaterial and milestone payments are mostly funded from sales after commercialisation. The focus for both parties is getting the drug to market while keeping upfront costs low for the company.

The broker believes the company will save time and risk with this deal, highlighting Elanco's success with other companies in getting a drug to market with as little hindrance as possible.

Speculative Buy. Target unchanged at 42c.

FORECAST
Morgans forecasts a full year FY25 dividend of 0.00 cents and EPS of 0.00 cents.
Morgans forecasts a full year FY26 dividend of 0.00 cents and EPS of 0.00 cents.

07/05/2025

1

Buy

$0.45

164.71%

Neurizon Therapeutics announced the last patient in its amyotrophic lateral sclerosis (ALS) open-label extension (OLE) study has completed 12 months of treatment with NUZ-001. This keeps top-line results on track for release in Q3 of 2025 notes Petra Capital.

Updated interim data continue to show compelling survival benefits, with NUZ-001 reducing the risk of death by -78.5% versus matched historical controls, highlights the analyst.

NUZ-001 offers offering a potential survival benefit of circa 11 months, well above the 3-6 month benefit of current ALS therapies, explains the broker. The drug remains safe and well-tolerated, with some patients now on treatment for over 30 months.

Petra Capital remains confident in NUZ-001’s potential, highlighting the superior survival trend and ongoing durability of response.

Target price of 45c and Buy rating are unchanged.

FORECAST
Petra Capital forecasts a full year FY25 dividend of 0.00 cents and EPS of minus -3.00 cents.
Petra Capital forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -3.20 cents.